Envoy Medical (COCH)Director bought ~$400K

~$400K

Approx. value · 1M sh @ $0.40

1.05M

Holds after · shares reported

Traded

Feb 12, 2026

Filed

Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 18, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
2. Feb 5, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 5, 2026 (the “ Award Date ”), the Compensation Committee of the Board of Directors of Envoy Medical, Inc. (the “ Company ”) approved the issuance of stock options to the Company’s Chief Executive Officer, Brent Lucas, and its Interim Chief Financial Officer, Robert Potashnick under the Company’s 2023 Equity Incentive Plan, as amended (the “ Equity Incentive Plan ”).”
3. Feb 11, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
4. Feb 12, 2026 · this disclosureInsider · 11 days before an 8-KDirector purchased ~$400K of COCH shares in the open market

What came next

1. Feb 12, 2026Insider · 5 peopleInsiders: 5 purchases (~$7.8M)
2. Feb 23, 2026Company filing · Form 8-K · Listing notice, Other newsReceived a notice from its stock exchange, and reported other company news“On February 23, 2026, Envoy Medical, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) in compliance with the Nasdaq Hearing Panel’s letter dated October 23, 2025.”
3. Mar 23, 2026Company filing · Form 8-K · ResultsReported its results
4. Mar 25, 2026Company filing · Form 8-K · Auditor changeChanged its auditor“Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm The Audit Committee (the “ Committee ”) of the Board of Directors of Envoy Medical, Inc. (the “ Company ”) conducted a competitive process to select the audit firm to serve as the Company’s independent registered public accounting firm beginning with the fiscal year ending December 31, 2026.”
5. Apr 15, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 15, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “ Board ”) of Envoy Medical, Inc. (the “ Company ”), the Board appointed Charles S. McKhann to serve as a Class I director, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.”
6. May 11, 2026Company filing · Form 8-K · ResultsReported its results
7. May 12, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On May 12, 2026, Envoy Medical, Inc. (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”).”
8. May 19, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously disclosed, on November 19, 2025, Envoy Medical, Inc. (the “Company”), received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its Class A Common Stock, par value $0.0001 per share (the “Common Stock”), had failed to comply with the $1.00 minimum bid price required for continued listing on The…”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Envoy Medical

OQRO holds no insider, Congress, fund or contract record for Envoy Medical dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its COCH page.

Other recent filings by Charles Brynelsen, Director

• SEC Form 4 at Envoy Medical (COCH)May 27, 2025
• SEC Form 4 at Envoy Medical (COCH)May 27, 2025
• SEC Form 4 at Envoy Medical (COCH)May 27, 2025

The full history of Charles Brynelsen, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Envoy Medical

• SEC Form 4Feb 17, 2026
• SEC Form 4Feb 17, 2026
• SEC Form 4Feb 17, 2026
• SEC Form 4Feb 17, 2026
• SEC Form 4Feb 17, 2026
• SEC Form 4Jun 13, 2025

Everything OQRO holds on this company is on its COCH page.